Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01000311 · ClinicalTrials.gov registry record · Phase 3
A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months
A Phase 3 study, sponsored by Novartis Vaccines.
- Completed
- Registry status
- Phase 3
- Development phase
- 529
- Enrollment target
NCT01000311 is a Phase 3 study that has completed, run by Novartis Vaccines. The registered enrollment target is 529 participants.
The verdict
NCT01000311, a Phase 3 study, has completed, sponsored by Novartis Vaccines.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 529 participants
- Enrollment target
Study Summary
This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.
Interventions
- BIOLOGICAL MenACWY-CRM
- BIOLOGICAL DTaP-IPV/Hib
- BIOLOGICAL HBV
- BIOLOGICAL PCV
- BIOLOGICAL MMR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 529 participants |
| Start Date | 2009-11 |
| Est. Completion | 2011-11 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01000311
The ClinicalTrials.gov registry entry for NCT01000311 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 529 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Vaccines, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which MenACWY-CRM is the first listed.
NCT01000311 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01000311 about?
NCT01000311 is a clinical study titled "A Study to Evaluate the Safety and Immunogenicity of 4 Doses of MenACWY Conjugate Vaccine, Administered Concomitantly With Routine Vaccines, Among Infants Aged 2 Months". This Phase 3 study is designed to demonstrate the safety and immunogenicity of MenACWY and non-interference of concomitant routine vaccines by MenACWY in an infant age group.
What is the current status of trial NCT01000311?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 529 participants. The study started on 2009-11. Estimated completion is 2011-11.
What interventions are being tested in trial NCT01000311?
The interventions under investigation include: MenACWY-CRM (BIOLOGICAL), DTaP-IPV/Hib (BIOLOGICAL), HBV (BIOLOGICAL), PCV (BIOLOGICAL), MMR (BIOLOGICAL).
Who is sponsoring clinical trial NCT01000311?
This trial is sponsored by Novartis Vaccines, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.